Aurinia Pharmaceuticals (AUPH) stock price is $16.74, up 1.52% on the day, as of Oct 20, 2026. It has a market cap of $2.18Bn and a P/E ratio of 6.94, and is classified in the Pharmaceuticals industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap2.18 Bn
P/E6.94
P/S7.00
Div. Yield0.00
Revenue Growth (1y) (Qtr)18.87
Add ratio to table…
About
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development and commercialization of therapies for autoimmune diseases with significant unmet medical needs. The company’s primary focus lies in treating lupus nephritis, a severe complication of systemic lupus erythematosus, through its flagship product, LUPKYNIS. Aurinia also advances a pipeline of investigational therapies, including aritinercept, a dual inhibitor targeting key pathways in…
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development and commercialization of therapies for autoimmune diseases with significant unmet medical needs. The company’s primary focus lies in treating lupus nephritis, a severe complication of systemic lupus erythematosus, through its flagship product, LUPKYNIS. Aurinia also advances a pipeline of investigational therapies, including aritinercept, a dual inhibitor targeting key pathways in autoimmune disease progression. Operating at the intersection of innovation and patient care, the company aims to address gaps in treatment options for complex autoimmune conditions.
The company generates revenue primarily through the sale of LUPKYNIS, its FDA-approved oral therapy for active lupus nephritis in adults. Sales are conducted directly in the United States via specialty pharmacies and a specialty distributor, while international markets, including Europe and Japan, are served through a collaboration with Otsuka Pharmaceutical Co., Ltd. Aurinia supplies LUPKYNIS inventory to Otsuka at cost plus a margin, earning additional milestone payments and royalties ranging from 10% to 20% on net sales in the Otsuka Territories. In 2025, net product sales reached $271.3 million, reflecting a 25% increase over the prior year.
The company operates through the following segments.
Commercialized Therapies: This segment centers on the marketing and distribution of LUPKYNIS, the first and only FDA-approved oral therapy for lupus nephritis. Aurinia manages direct sales in the U. S. through its commercial organization, while Otsuka handles commercialization in Japan, Europe, the U. K., and Switzerland. The segment also includes revenue from supply agreements, milestone payments, and royalties tied to LUPKYNIS sales in international markets.
Research and Development: This segment focuses on the advancement of aritinercept, a dual inhibitor of BAFF and APRIL, designed to treat a broader spectrum of autoimmune diseases. Aritinercept is currently in early-stage clinical development, with plans to initiate studies in additional autoimmune indications by 2026. The segment encompasses preclinical and clinical trial activities, regulatory strategy, and intellectual property protection for pipeline assets.
Aurinia Pharmaceuticals Inc. holds a distinctive position in the autoimmune disease treatment landscape, particularly in lupus nephritis, where LUPKYNIS remains the only FDA-approved oral therapy. The company competes with injectable alternatives such as GSK’s BENLYSTA and Genentech’s GAZYVA, as well as off-label use of older immunosuppressants like tacrolimus. Aurinia’s competitive advantages include LUPKYNIS’s oral administration, which enhances patient convenience, and its robust clinical data demonstrating rapid proteinuria reduction and improved renal outcomes. The drug’s dual mechanism of action, targeting calcineurin inhibition and immune modulation, further differentiates it from existing treatments. In the broader autoimmune space, aritinercept faces competition from other dual BAFF/APRIL inhibitors, but its engineered high-affinity binding and favorable immunoglobulin reduction profile may provide a therapeutic edge.
The company’s customer base primarily consists of patients with active lupus nephritis, a severe autoimmune condition affecting the kidneys. In the U. S., LUPKYNIS is distributed through specialty pharmacies and a specialty distributor, serving healthcare providers and institutions that treat lupus patients. Internationally, Aurinia’s collaboration partner, Otsuka Pharmaceutical Co., Ltd., markets the drug to healthcare systems and providers in Europe, Japan, the U. K., and Switzerland. The end users are individuals suffering from lupus nephritis, a subset of the broader systemic lupus erythematosus population, which is estimated to include over 200,000 people in the U. S. alone.
Sector:HealthcareSector rationaleAurinia Pharmaceuticals is a biopharmaceutical company that develops and sells medical therapies, specifically LUPKYNIS for lupus nephritis. Its revenue is derived from the sale of this FDA-approved drug and royalties from its pharmaceutical partner, Otsuka Pharmaceutical, which fits squarely within the Pharmaceuticals industry of the Healthcare sector.Industries:PharmaceuticalsPharmaceuticalsPrimaryAurinia Pharmaceuticals develops and markets branded prescription drugs, specifically its flagship oral therapy LUPKYNIS for lupus nephritis. The company generates the majority of its revenue from the direct sale of this branded pharmaceutical product in the U.S. and through royalties and supply agreements internationally.BiotechnologyBiotechnologySecondaryThe company maintains a research and development pipeline focused on aritinercept, a dual inhibitor of BAFF and APRIL designed to treat autoimmune diseases. This activity involves the development of biological therapies derived from biological science, which is characteristic of biotechnology.Classified using BQ-MICSCIK: 0001600620
Bull & bear
Investment Thesis
▲ Bull case
Aurinia Pharmaceuticals Inc. is positioned for sustained growth driven by the expanding market penetration of LUPKYNIS as a standard-of-care therapy for lupus nephritis, with recent EULAR 2026 data showing a 53% reduction in renal-related event or death risk and an 81% reduction in death risk, which significantly strengthens its clinical differentiation and supports broader adoption beyond current prescribing patterns, particularly as real-world evidence accumulates and payer preferences evolve toward therapies with proven hard outcome benefits.
The company's solid financial foundation, evidenced by $378.8 million in cash and investments as of March 31, 2026, provides ample runway to execute its strategic priorities without dilution risk, including the advancement of aritinercept into multiple autoimmune disease indications and continued investment in LUPKYNIS commercial expansion, while the ongoing $150 million share repurchase program signals management's confidence in intrinsic value and supports earnings per share accretive growth.
Leadership changes under CEO Kevin Tang, including zero executive compensation and the appointment of a disciplined COO and CFO, reflect a structural shift toward shareholder-aligned capital allocation, reducing historical concerns about excessive executive payouts and enabling reinvestment into high-return commercial and R&D initiatives, which could unlock latent value in the aritinercept pipeline as it progresses through clinical development for broader autoimmune applications.
Aurinia's 2026 revenue guidance of $315 million to $325 million, representing 11% to 15% year-over-year growth, is underpinned by durable LUPKYNIS demand dynamics rather than transient factors, as the drug has demonstrated consistent quarter-over-quarter net product sales growth from $59.971 million in Q1 2025 to $73.563 million in Q1 2026, indicating a sustainable adoption trajectory supported by increasing physician familiarity and favorable reimbursement landscapes in key markets.
The transition to performance-based equity awards and the discontinuation of time-based RSUs under the new management team aligns employee incentives with long-term value creation, reducing the risk of misallocated capital and enhancing focus on milestones that drive both clinical progress in aritinercept and commercial execution for LUPKYNIS, which could accelerate pipeline value inflection points sooner than market expectations.
Aurinia Pharmaceuticals Inc. is positioned for sustained growth driven by the expanding market penetration of LUPKYNIS as a standard-of-care therapy for lupus nephritis, with recent EULAR 2026 data showing a 53% reduction in renal-related event or death risk and an 81% reduction in death risk, which significantly strengthens its clinical differentiation and supports broader adoption beyond current prescribing patterns, particularly as real-world evidence accumulates and payer preferences evolve toward therapies with proven hard outcome benefits.
The company's solid financial foundation, evidenced by $378.8 million in cash and investments as of March 31, 2026, provides ample runway to execute its strategic priorities without dilution risk, including the advancement of aritinercept into multiple autoimmune disease indications and continued investment in LUPKYNIS commercial expansion, while the ongoing $150 million share repurchase program signals management's confidence in intrinsic value and supports earnings per share accretive growth.
Leadership changes under CEO Kevin Tang, including zero executive compensation and the appointment of a disciplined COO and CFO, reflect a structural shift toward shareholder-aligned capital allocation, reducing historical concerns about excessive executive payouts and enabling reinvestment into high-return commercial and R&D initiatives, which could unlock latent value in the aritinercept pipeline as it progresses through clinical development for broader autoimmune applications.
Aurinia's 2026 revenue guidance of $315 million to $325 million, representing 11% to 15% year-over-year growth, is underpinned by durable LUPKYNIS demand dynamics rather than transient factors, as the drug has demonstrated consistent quarter-over-quarter net product sales growth from $59.971 million in Q1 2025 to $73.563 million in Q1 2026, indicating a sustainable adoption trajectory supported by increasing physician familiarity and favorable reimbursement landscapes in key markets.
The transition to performance-based equity awards and the discontinuation of time-based RSUs under the new management team aligns employee incentives with long-term value creation, reducing the risk of misallocated capital and enhancing focus on milestones that drive both clinical progress in aritinercept and commercial execution for LUPKYNIS, which could accelerate pipeline value inflection points sooner than market expectations.
Aurinia Pharmaceuticals Inc. faces significant near-term pressure on profitability and cash flow sustainability, as evidenced by a sequential decline in cash position from $398.0 million at December 31, 2025 to $378.8 million at March 31, 2026, driven by $53.7 million in financing outflows including $36.2 million in share repurchases and $14.6 million in tax withholdings, which raises concerns about whether ongoing capital return programs can be maintained without compromising essential R&D funding for aritinercept development.
Despite strong top-line growth, the company's operating model remains vulnerable to macroeconomic and pricing pressures, as reflected in the Q1 2026 income statement where income tax expense rose sharply to $9.570 million from $1.005 million in the prior year period, significantly impacting net income conversion and suggesting potential limitations in leveraging deferred tax assets or changes in jurisdictional income mix that could undermine earnings quality going forward.
The commercial success of LUPKYNIS is still concentrated in a niche indication—lupus nephritis—with no guarantee of expansion into larger autoimmune markets, and the aritinercept pipeline, while promising, remains in early clinical stages with no near-term data readouts expected to catalyze re-rating, leaving the company overly dependent on a single product whose long-term durability is unproven beyond the initial adoption phase.
Aurinia's reliance on share repurchases as a primary capital allocation tool—$98.2 million for the full year 2025 and $36.2 million in Q1 2026—may signal a lack of compelling internal investment opportunities, particularly if aritinercept fails to demonstrate differentiation in competitive BAFF/APRIL inhibitor landscapes, raising questions about whether the repurchase program is substituting for genuine growth investment rather than reflecting true excess capital.
The leadership transition, while viewed positively by activist shareholders, introduces execution risk as CEO Kevin Tang transitions from Chair to operational role without prior experience as a CEO in a commercial-stage biopharmaceutical company, and the appointment of new CFO and COO with base salaries of $300,000 may not be sufficient to attract or retain top-tier talent in a competitive industry, potentially undermining the effectiveness of the new management team over time.
Aurinia Pharmaceuticals Inc. faces significant near-term pressure on profitability and cash flow sustainability, as evidenced by a sequential decline in cash position from $398.0 million at December 31, 2025 to $378.8 million at March 31, 2026, driven by $53.7 million in financing outflows including $36.2 million in share repurchases and $14.6 million in tax withholdings, which raises concerns about whether ongoing capital return programs can be maintained without compromising essential R&D funding for aritinercept development.
Despite strong top-line growth, the company's operating model remains vulnerable to macroeconomic and pricing pressures, as reflected in the Q1 2026 income statement where income tax expense rose sharply to $9.570 million from $1.005 million in the prior year period, significantly impacting net income conversion and suggesting potential limitations in leveraging deferred tax assets or changes in jurisdictional income mix that could undermine earnings quality going forward.
The commercial success of LUPKYNIS is still concentrated in a niche indication—lupus nephritis—with no guarantee of expansion into larger autoimmune markets, and the aritinercept pipeline, while promising, remains in early clinical stages with no near-term data readouts expected to catalyze re-rating, leaving the company overly dependent on a single product whose long-term durability is unproven beyond the initial adoption phase.
Aurinia's reliance on share repurchases as a primary capital allocation tool—$98.2 million for the full year 2025 and $36.2 million in Q1 2026—may signal a lack of compelling internal investment opportunities, particularly if aritinercept fails to demonstrate differentiation in competitive BAFF/APRIL inhibitor landscapes, raising questions about whether the repurchase program is substituting for genuine growth investment rather than reflecting true excess capital.
The leadership transition, while viewed positively by activist shareholders, introduces execution risk as CEO Kevin Tang transitions from Chair to operational role without prior experience as a CEO in a commercial-stage biopharmaceutical company, and the appointment of new CFO and COO with base salaries of $300,000 may not be sufficient to attract or retain top-tier talent in a competitive industry, potentially undermining the effectiveness of the new management team over time.